Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 Nov 4, 2024 FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report third quarter 2024 financial results on November 12, 2024. Mirum will also host a conference call to discuss the third quarter…
Oct 27, 2023 FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report third quarter 2023 financial results on Thursday, November 2nd, 2023. Mirum will also host a conference call to discuss the third quarter 2023 financial results and recent corporate progress. Conference call details:Thursday, November 2nd, 20234:30 p.m. ET /…
Jul 27, 2023 FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report second quarter 2023 financial results on Thursday, August 3, 2023. Mirum will also host a conference call to discuss the second quarter 2023 financial results and recent corporate progress. Conference call details:Thursday, August 3, 20234:30 p.m. ET…
FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report fourth quarter and year-end 2022 financial results on Wednesday, March 8, 2023. Mirum will also host a conference call to discuss the fourth quarter and year-end 2022 financial results and recent corporate progress. Conference call details:Wednesday, March 8, 20234:30 p.m. ET…
Apr 27, 2023 FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2023 financial results on Thursday, May 4, 2023. Mirum will also host a conference call to discuss the first quarter 2023 financial results and recent corporate progress. Conference call details:Thursday, May 4, 20234:30 p.m. ET /…
– sNDA submitted for the treatment of cholestatic pruritus in patients two months of age and older with progressive familial intrahepatic cholestasis (PFIC) – Submission based on MARCH Phase 3 study with high statistical significance (p<0.0001) between LIVMARLI versus placebo, and 62% of itch severity scores reported as mild to none – If approved, LIVMARLI…
